These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 32435850)
1. Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors. Hashimoto A; Fukumoto T; Zhang R; Gabrilovich D Cancer Immunol Immunother; 2020 Sep; 69(9):1929-1936. PubMed ID: 32435850 [TBL] [Abstract][Full Text] [Related]
2. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201 [TBL] [Abstract][Full Text] [Related]
3. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460 [TBL] [Abstract][Full Text] [Related]
4. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines. Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549 [TBL] [Abstract][Full Text] [Related]
5. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. Sasidharan Nair V; Saleh R; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Alajez NM; Abu Nada M; Elkord E Clin Epigenetics; 2020 Jan; 12(1):13. PubMed ID: 31941522 [TBL] [Abstract][Full Text] [Related]
6. Differences in Functional Expression of Connexin43 and Na Zhang X; Patel D; Xu Q; Veenstra R Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30081552 [TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. Wang HF; Ning F; Liu ZC; Wu L; Li ZQ; Qi YF; Zhang G; Wang HS; Cai SH; Du J Cancer Immunol Immunother; 2017 Mar; 66(3):355-366. PubMed ID: 27915371 [TBL] [Abstract][Full Text] [Related]
8. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot. Beyer M; Kiweler N; Mahboobi S; Krämer OH Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834 [TBL] [Abstract][Full Text] [Related]
9. Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment. Sidiropoulos DN; Rafie CI; Jang JK; Castanon S; Baugh AG; Gonzalez E; Christmas BJ; Narumi VH; Davis-Marcisak EF; Sharma G; Bigelow E; Vaghasia A; Gupta A; Skaist A; Considine M; Wheelan SJ; Ganesan SK; Yu M; Yegnasubramanian S; Stearns V; Connolly RM; Gaykalova DA; Kagohara LT; Jaffee EM; Fertig EJ; Roussos Torres ET Cancer Immunol Res; 2022 May; 10(5):656-669. PubMed ID: 35201318 [TBL] [Abstract][Full Text] [Related]
10. Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer. Tcyganov EN; Hanabuchi S; Hashimoto A; Campbell D; Kar G; Slidel TW; Cayatte C; Landry A; Pilataxi F; Hayes S; Dougherty B; Hicks KC; Mulgrew K; Tang CA; Hu CA; Guo W; Grivennikov S; Ali MA; Beltra JC; Wherry EJ; Nefedova Y; Gabrilovich DI J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34228641 [TBL] [Abstract][Full Text] [Related]
11. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors. Koppel I; Timmusk T Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482 [TBL] [Abstract][Full Text] [Related]
12. Visualization and quantification of Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525 [TBL] [Abstract][Full Text] [Related]
13. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263 [TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249 [No Abstract] [Full Text] [Related]
15. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935 [TBL] [Abstract][Full Text] [Related]
18. The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192 [TBL] [Abstract][Full Text] [Related]
19. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells. Cui Y; Cai J; Wang W; Wang S Front Immunol; 2021; 12():690207. PubMed ID: 34149732 [TBL] [Abstract][Full Text] [Related]
20. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]